Sunshine Biopharma Inc. (SBFM) - Form 8-K Summary
Business Context and Reporting Period
Sunshine Biopharma, Inc., a Colorado corporation, filed this Current Report on Form 8-K on April 1, 2024. The filing serves to announce the Company's financial results for the period ended December 31, 2023, via a press release attached as Exhibit 99.1. The Company's common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols SBFM and SBFMW, respectively.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text provided for this summary.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the year ended December 31, 2023.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer under General Instruction B.2 of Form 8-K. It states that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liability of that section. Consequently, this information will not be incorporated by reference into other filings unless expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed in the text of the 8-K itself.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific revenue, net loss, and cash position figures for the year ended December 31, 2023.
- Verify the Company's cash runway and burn rate, as these are critical for biopharma entities and are not listed in the 8-K cover text.
- Confirm any updates to clinical trial milestones or regulatory status mentioned in the full press release.
- Check for any new debt obligations or equity financing activities disclosed in the full financial results.